New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?

Antibodies, Monoclonal / pharmacology Female Humans Male Urologic Neoplasms / drug therapy
Bladder cancer Enfortumab vedotin Nectin-4 Upper tract urothelial cancer

Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
10 2021
Historique:
received: 03 05 2021
accepted: 07 05 2021
pubmed: 22 6 2021
medline: 19 2 2022
entrez: 21 6 2021
Statut: ppublish

Résumé

Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV.

Identifiants

DOI: 10.1016/j.urolonc.2021.05.013 PMID: 34148797
pubmed: 34148797
pii: S1078-1439(21)00219-2
doi: 10.1016/j.urolonc.2021.05.013
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
enfortumab vedotin DLE8519RWM

Types de publication

News

Langues

eng

Sous-ensembles de citation

IM

Pagination

619-622

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Jean Hoffman-Censits (J)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Departments of Medical Oncology and Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. Electronic address: Jhoffm57@jhmi.edu.

Kara Lombardo (K)

Department of Urology & Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD.

David McConkey (D)

Director, Johns Hopkins Greenberg Bladder Cancer Institute, Professor, The James Buchanan Brady Urological Institute, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD.

Noah M Hahn (NM)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Departments of Medical Oncology and Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD.

Babar Bashir (B)

Sidney Kimmel Medical College at Thomas Jefferson University, Department of Medical Oncology, Philadelphia, PA.

Wm Kevin Kelly (WK)

Sidney Kimmel Medical College at Thomas Jefferson University, Departments of Medical Oncology and Urology, Philadelphia, PA.

Burles Johnson (B)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Medical Oncology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD.

Andres Matoso (A)

Johns Hopkins Hospital, Departments of Pathology, Urology and Oncology, Baltimore, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › New and topics: enfortumab vedotin mechanisms...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › New and topics: enfortumab vedotin mechanisms...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › New and topics: enfortumab vedotin mechanisms...